kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - outros agentes antineoplásicos - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
adriblastina
laboratÓrios pfizer ltda - antibioticos antineoplasicos
acido zoledronico
antibiÓticos do brasil ltda - ácido zoledrônico monoidratado - supressores da reabsorcao ossea
afinitor
novartis biociencias s.a - everolimo - antineoplasico
amgevita
amgen biotecnologia do brasil ltda. - adalimumabe - antinflamatorios antireumaticos
aminofilina
hipolabor farmaceutica ltda - aminofilina - broncodilatadores
aminofilina
hypofarma - instituto de hypodermia e farmÁcia ltda - aminofilina - broncodilatadores
aminofilina
laboratÓrio teuto brasileiro s/a - aminofilina - broncodilatadores
amoxicilina
sanofi medley farmacÊutica ltda. - amoxicilina tri-hidratada - penicilina de amplo espectro
amoxicilina + clavulanato de potassio
ems s/a - amoxicilina, clavulanato de potÁssio - antibioticos sistemicos-associacoes medicamentosas